Class Action Lawsuit Filed Against Aquestive Therapeutics Over Alleged Securities Fraud
A class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) over alleged securities fraud. The lawsuit follows the FDA's rejection of Anaphylm's New Drug Application, which caused a 37.04% drop in Aquestive's stock price. Investors are being urged to contact the law firm for potential involvement in the class action.
Tickers: $AQST
Topics: class action FDA approval regulatory action securities fraud stock price drop